Clinical Trials

42 enrolled 12 charts

Melanoma

NCT04796194 2025-11-20

ATLAS-IT-05

23 enrolled

Phase EARLY_PHASE1 Completed

Melanoma

NCT03276832 2025-10-28

Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma

7 enrolled

Melanoma

NCT04700072 2025-10-28

KEYMAKER-U02

56 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

DermatologicGastrointestinal

89 enrolled 24 charts

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT05665595 2025-10-15

KEYVIBE-010

Phase 3 Completed

1,594 enrolled 12 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03715205 2025-08-29

Keynote-593

Phase 4 Completed

150 enrolled 14 charts

DermatologicThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04305041 2025-08-29

KEYMAKER-U02

100 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT02752074 2025-08-24

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Phase 3 Completed

706 enrolled 17 charts

Melanoma

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT02681549 2025-08-07

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

41 enrolled 20 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05304546 2025-07-22

MK3475-C01

1 enrolled

Phase EARLY_PHASE1 Completed

Melanoma, Neoplasms

NCT04581382 2025-07-10

Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma

18 enrolled

Melanoma

NCT02680184 2025-07-04

Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy

199 enrolled

Melanoma

NCT02318771 2025-05-15

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

41 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

191 enrolled 26 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03665597 2025-02-10

KEYNOTE-555

138 enrolled 34 charts 2 FDA

Melanoma

NCT02500576 2025-01-15

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

18 enrolled 13 charts

Melanoma

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

74 enrolled

Melanoma

NCT04068181 2025-01-07

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

72 enrolled 28 charts

Melanoma

NCT03092453 2024-12-24

Dendritic Cell Vaccination in Patients With Advanced Melanoma

5 enrolled 10 charts

Melanoma

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT02791594 2024-11-08

Imaging FDG Flare in Melanoma

Completed

21 enrolled 10 charts

Melanoma

NCT03341143 2024-10-30

Fecal Microbiota Transplant (FMT) in Melanoma Patients

20 enrolled 19 charts

Melanoma

NCT03875079 2024-10-03

A Study to Evaluate Safety and Therapeutic Activity of RO6874281 in Combination with Pembrolizumab, in Participants with Advanced or Metastatic Melanoma

83 enrolled

Melanoma

NCT03200847 2024-10-01

Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma

26 enrolled 13 charts

Melanoma

NCT03620019 2024-08-12

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

25 enrolled 16 charts

Melanoma

NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

DermatologicGastrointestinalLymphoidSarcomaThoracic

58 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

NCT02821000 2024-05-30

Keynote-151

103 enrolled 30 charts

Melanoma

NCT02600169 2024-05-06

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

Completed

150 enrolled

Melanoma

NCT04148937 2024-04-05

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

52 enrolled 21 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT03329950 2024-03-28

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

132 enrolled

Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Esophageal Neoplasms, Fallopian Tube Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Laryngeal Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mouth Neoplasms, Oropharyngeal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Cholangiocarcinoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Hyper-IgM Immunodeficiency Syndrome

NCT03590054 2024-03-22

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

35 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ureteral Neoplasms

NCT03765229 2024-01-10

An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma

11 enrolled 12 charts

Melanoma

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

DermatologicGenitourinaryHead & NeckLymphoidThoracic

14 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lymphoma, Melanoma, Neoplasm Metastasis

NCT03089606 2023-11-15

Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker

27 enrolled 14 charts

Melanoma

NCT02407171 2023-10-31

Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

61 enrolled 14 charts

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT02515227 2023-08-25

Mel64

22 enrolled 7 charts

Melanoma

NCT04452214 2023-07-14

A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors

19 enrolled

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma

NCT02575404 2023-06-05

GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients